Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: Marty who wrote (683)	6/17/1999 2:21:00 PM
From: Marty	Read Replies (1) \| Respond to of 705

Here is a quote from this week's BusinessWeek, page 46, about Genentech and Roche. "Genentech CEO Art Levinson says he expects Roche to opt in sooner rather than later because of the penalty for waiting. Besides, he argues, it's cheaper and faster to run international clinical trials concurrent with those in the United States. The deal 'is a tribute to Roche's creativity,' he says." This is exactly what NEOT did last month for the same reasons, so it should be a tribute to their creativity as well. I doubt if Roche told them to do it that way. Anybody else feel that the train is starting to leave the station?